Cadrenal Therapeutics, Inc., a leading biopharmaceutical company establishing a tr5ansformative and excellent therapeutics to conquer over the limitations of the latest anticoagulation therapy has confirmed that their members of the management teak along with the CEO, Quang X. Pham, will be conducting a investor and partnering meeting during the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 12-15, 2026.
Cadrenal will be attending the conference as well as the meeting, which will be worth visiting San Francisco. For Cadrenal, this opportunity is fruitful as the company is seeking a valuable partnership and investors to expand its pipeline and business overall.
The CEO of Cadrenal Therapeutics, Quang X. Pham, said, “Being a part of the J.P. Morgan Healthcare Conference in San Francisco is the best of the best opportunity for our company to meet the latest and prospective investors and partners. We are looking for a valuable meeting to present our smart strategies and the latest two of the acqyuisitions that have been made in 2025 to uplift our mission.”
“Our mission is to establish novel classified products that cover the gap between the current chronic and acute anticoagulation management for high-risk and rare patient groups.”
Cadrenal is way too concentrated on identifying the gaps in the $40 billion anticoagulation market. Cadrenal’s pipeline involves VLX-1005, Frunexian, and Tecarfarin. Each of the pipeline marks a potential value that will encourage confidence and conversation in the meeting. The VLX-1005 is a phase 2, best and excellent in class parenteral (intravenous) 12-Lipoxygenase (12-LOX) inhibitor engineered to stop the major hurdles in the immune-mediated platelet activation.
This inhibits thrombus formation and stops platelet activation. The trial includes the speedy designation and ODD for heparin-induced thrombocytopenia (HIT) patients. Frunexian is a phase 2-ready acute parenteral Factor XIa (FXIa) inhibitor. The trial is initiated for continuous renal replacement therapy (CRRT) and complex cardiac surgery patients. The Tecarfarin is a phase 3-ready, oral Vitamin K antagonist (VKA) with a qualified mechanism of action (MoA) similar to warfarin. But it's truly a different and desirable metabolic study than warfarin.
The trial features a speedy designation and an orphan drug designation (ODD) for the end-stage kidney disease (ESKD) patients suffering from atrial fibrillation (AFib). The ODD for patients engaging a left ventricular assist device (LVAD) was enrolled in partnership with Abbott.
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
